Published in J Am Soc Nephrol on January 02, 2015
IgG Donor-Specific Anti-Human HLA Antibody Subclasses and Kidney Allograft Antibody-Mediated Injury. J Am Soc Nephrol (2015) 1.07
Value of Donor-Specific Anti-HLA Antibody Monitoring and Characterization for Risk Stratification of Kidney Allograft Loss. J Am Soc Nephrol (2016) 0.79
The Banff 2015 Kidney meeting report: Current challenges in rejection classification and prospects for adopting molecular pathology. Am J Transplant (2016) 0.78
Developing renal allograft surveillance strategies - urinary biomarkers of cellular rejection. Can J Kidney Health Dis (2015) 0.77
Begin at the Beginning to Prevent the End. J Am Soc Nephrol (2015) 0.76
Clinically relevant interpretation of solid phase assays for HLA antibody. Curr Opin Organ Transplant (2016) 0.76
Antibody-Mediated Rejection: A Review. Ochsner J (2017) 0.75
Progression of Interstitial Fibrosis in Kidney Transplantation. Clin J Am Soc Nephrol (2016) 0.75
Acute Rejection Phenotypes in the Current Era of Immunosuppression: A Single-Center Analysis. Transplant Direct (2017) 0.75
Prediction of Long-term Renal Allograft Outcome By Early Urinary CXCL10 Chemokine Levels. Transplant Direct (2015) 0.75
From Humoral Theory to Performant Risk Stratification in Kidney Transplantation. J Immunol Res (2017) 0.75
Non-invasive approaches in the diagnosis of acute rejection in kidney transplant recipients, part II: omics analyses of urine and blood samples. Clin Kidney J (2016) 0.75
Non-invasive approaches in the diagnosis of acute rejection in kidney transplant recipients. Part I. In vivo imaging methods. Clin Kidney J (2016) 0.75
Not All Antibodies Are Created Equal: Factors That Influence Antibody Mediated Rejection. J Immunol Res (2017) 0.75
Unraveling the Role of Allo-Antibodies and Transplant Injury. Front Immunol (2016) 0.75
Orthogonal Comparison of Molecular Signatures of Kidney Transplants With Subclinical and Clinical Acute Rejection: Equivalent Performance Is Agnostic to Both Technology and Platform. Am J Transplant (2017) 0.75
Chronic Antibody-Mediated Rejection in Nonhuman Primate Renal Allografts: Validation of Human Histological and Molecular Phenotypes. Am J Transplant (2017) 0.75
Current status of pediatric renal transplant pathology. Pediatr Nephrol (2016) 0.75
Kidney Transplant with Low Levels of DSA or Low Positive B-Flow Crossmatch: An Underappreciated Option for Highly-Sensitized Transplant Candidates. Transplantation (2016) 0.75
A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med (1999) 82.86
The Banff 97 working classification of renal allograft pathology. Kidney Int (1999) 9.02
The natural history of chronic allograft nephropathy. N Engl J Med (2003) 8.70
Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant (2008) 8.09
Desensitization in HLA-incompatible kidney recipients and survival. N Engl J Med (2011) 6.72
Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant (2007) 5.39
Antibody-mediated rejection criteria - an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant (2003) 4.54
Long-term renal allograft survival in the United States: a critical reappraisal. Am J Transplant (2010) 4.09
Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Transplant (2011) 4.06
Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant (2014) 3.43
Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol (2010) 2.66
Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure. Transplantation (2010) 2.59
Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant (2012) 2.46
Banff 2011 Meeting report: new concepts in antibody-mediated rejection. Am J Transplant (2012) 2.28
The natural history of acute histologic rejection without biochemical graft dysfunction in orthotopic liver transplantation: a systematic review. Liver Transpl (2002) 2.05
Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplant (2011) 1.98
Protocol biopsy of the stable renal transplant: a multicenter study of methods and complication rates. Transplantation (2003) 1.79
Outcome of subclinical antibody-mediated rejection in kidney transplant recipients with preformed donor-specific antibodies. Am J Transplant (2009) 1.67
Beneficial effects of treatment of early subclinical rejection: a randomized study. J Am Soc Nephrol (1998) 1.54
Diagnosis and prevention of chronic kidney allograft loss. Lancet (2011) 1.52
Comparison of combination Plasmapheresis/IVIg/anti-CD20 versus high-dose IVIg in the treatment of antibody-mediated rejection. Am J Transplant (2009) 1.52
Subclinical rejection associated with chronic allograft nephropathy in protocol biopsies as a risk factor for late graft loss. Am J Transplant (2006) 1.50
Organ Procurement and Transplantation Network and Scientific Registry of Transplant Recipients 2010 data report. Am J Transplant (2011) 1.46
Five-year outcomes in living donor kidney transplants with a positive crossmatch. Am J Transplant (2012) 1.31
Histological findings in early routine biopsies of stable renal allograft recipients. Transplantation (1994) 1.19
Subclinical acute antibody-mediated rejection in positive crossmatch renal allografts. Am J Transplant (2007) 1.10
Asymptomatic antibody-mediated rejection after heart transplantation predicts poor outcomes. J Heart Lung Transplant (2009) 1.06
Combined posttransplant prophylactic IVIg/anti-CD 20/plasmapheresis in kidney recipients with preformed donor-specific antibodies: a pilot study. Transplantation (2010) 1.03
Cardiovascular mortality among heart transplant recipients with asymptomatic antibody-mediated or stable mixed cellular and antibody-mediated rejection. J Heart Lung Transplant (2009) 1.03
Antibody-mediated allograft rejection: morphologic spectrum and serologic correlations in surveillance and for cause biopsies. Transplantation (2013) 0.88
Complications of protocol renal biopsy. Transplantation (2004) 0.85
Clinical and subclinical acute rejection early after liver transplantation: contributing factors and relevance for the long-term course. Transplantation (2001) 0.83
The utility of 1- and 3-month protocol biopsies on renal allograft function: a randomized controlled study. Am J Transplant (2007) 0.81